← Eichor
Study identifier: NCT06527027 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes

Condition: Lymph Node Neoplasm · Lymph Node Metastasis  ·  Sponsor: Copernicus Memorial Hospital

PhaseNA
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The project aims to evaluate the value of the new LN-RADS scales for lymph node classification in CT and MR and to compare this method with two other methods RECIST 1.1 and Node-RADS. The main tested system in the study is LN-RADS, the comparators are RECIST 1.1 and Node-RADS criteria. Lymph nodes are a key diagnostic and therapeutic element in oncology. Despite the technological progress, the detection of neoplastic changes in the lymph nodes is of low effectiveness, which results from the imperfection of the criteria used. Currently, the most widely used criterion is the RECIST 1.1 guideline developed in the 1990s, according to which the lymph node dimension in the short axis with a cut-off point of 10 mm is decisive. Lymph nodes smaller than 10 mm across are considered normal. It is a criterion with a high error rate, both due to the false-negative diagnoses (with small metastases below 10 mm) and false-positive diagnoses (in the case of inflammatory lymphadenopathy). A particular disadvantageous situation is when the metastatic nodes and their transverse dimension is less than 10 mm, because they are treated as healthy nodes and the degree of the disease advancement is underestimated. As a result, the patient is not treated properly - no complete lymphadenectomy, no radiotherapy to the area of these nodes or insufficient systemic treatment. In all cases, underestimating the stage of the neoplastic diseases increases the risk of the recurrence. LN-RADS accounts small m…

This description comes directly from the study's public registry record.

Talk to the study team

Cezary Chudobiński, PhD  ·  +4842 689 58 99  ·  cezary.chudobinski@wp.pl

Always discuss trial participation with your own doctor first.

Locations (6)

Maria Skłodowska-Curie National Research Institute of Oncology - National Research InstituteKrakow, PolandActive Not Recruiting
Copernicus Memorial HospitalLodz, PolandRecruiting
Independent Public Healthcare Centre (SPZOZ) , University Clinical Hospital No. 2 of the Medical University of ŁódźLodz, PolandActive Not Recruiting
Doradztwo i Zarządzanie w Opiece Zdrowotnej A.K. Sp.z o.oWarsaw, PolandActive Not Recruiting
Maria Skłodowska-Curie National Research Institute of Oncology - National Research InstituteWarsaw, PolandActive Not Recruiting
Professor Orłowski Hospital in Warsaw , Independent Public Healthcare CentreWarsaw, PolandActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06527027